Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have received a consensus rating of "Buy" from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $37.57.

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a report on Tuesday, January 7th. Oppenheimer dropped their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, Bank of America reduced their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, March 10th.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in DNLI. Sterling Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Denali Therapeutics during the 4th quarter worth approximately $62,000. Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $65,000. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Denali Therapeutics by 253.8% during the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock worth $108,000 after buying an additional 5,705 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Stock Up 1.5 %

Shares of NASDAQ DNLI opened at $12.74 on Friday. The stock has a market cap of $1.85 billion, a PE ratio of -4.62 and a beta of 1.58. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $33.33. The business has a 50-day moving average price of $15.62 and a 200 day moving average price of $21.26.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. Sell-side analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.